

AcouSort AB Press release,
August 04, 2022

AcouSort's and Werfen's joint patent application has received national approval in the US

AcouSort AB (publ) ("AcouSort", the "Company") today announces that the Company's and its partner Werfen's ("Werfen") (formerly Instrumentation Laboratory Company) U.S. patent application received national approval in the United States on August 3, 2022. According to PCT regulations, the original international application was published in the database after April 7, 2018. The patent application concerns an acoustofluidics technology that separates blood plasma from whole blood and enables analysis of the plasma using either optical or electrical methods. The technology to which the patent application relates has been developed in collaboration between AcouSort and Werfen. The collaboration has resulted in Werfen using AcouSort's acoustics technology in the next generation of one of their clinical diagnostic instruments.

About the joint patent application

On October 7, 2016, AcouSort and Werfen filed a joint patent application entitled "*Method and system for optical or electrical measurements in disperse fluids*" with application number PCT/EP2017/075681. The patent application concerns a technology that, using ultrasound in a microchannel, separates blood plasma from whole blood and enables analysis of the plasma using either optical or electrical measurement methods. The technology in the patent application has been developed in a collaboration between AcouSort and Werfen and the patent application includes inventors from both companies. The now obtained national patent in the US is valid for 20 years from the time of the international application, i.e., until October 2037.

CEO Torsten Freltoft comments

"Werfen has implemented our common technology in the next generation of one of their product families and in the autumn of 2021, AcouSort launched the new product AcouPlasmaOptical based on the patent. The national approval we and Werfen have now received in the US means a lot for our continued cooperation and strengthens the protection of our respective commercial activities in a significant way."

For further information about AcouSort, please contact:

Torsten Freltoft, CEO

Phone: +45 2045 0854

Email: torsten.freltoft@acousort.com

About AcouSort

AcouSort AB (corporate registration number 556824-1037) is an innovative technology company focusing on developing products and solutions for integrated preparation of biological samples. With the help of sound waves, the company's products can separate blood cells, concentrate, purify and stain cells, exosomes and bacteria from biological samples. The technology of the company's products is acoustofluidics, where sound waves

and microfluidics enable automated handling of samples in a range of application areas, from research on new biomarkers to the development of new diagnostic systems for near-patient testing – so-called Point-of Care (POC) systems. The company's commercialization strategy is based on the already proven business model of providing separation modules to diagnostic system manufacturers for integrated sample preparation as well as to continue the commercialization of the company's research instruments. With the help of the company's products and development of point-of-care tests, new diagnostic systems and treatments are enabled, addressing some of the most challenging disease areas of our time: cancer, infectious diseases and cardiovascular diseases. AcouSort is listed at Nasdaq First North Growth Market. The company's Certified Adviser is Erik Penser Bank, 08-463 83 00, mail to: certifiedadviser@penser.se Erik Penser Bank AB (publ), Apelbergsgatan 27, Box 7405, 103 91 Stockholm.